Most dual users either continue dual use or transition to exclusive conventional cigarette use
Maximal survival benefit seen for smoking cessation treatment within six months of diagnosis
Higher levels of smoking also tied to pain-related work limitations and worse self-reported health, mental health
Two-thirds of adults who smoked wanted to quit, about half made a quit attempt, but only 8.8 percent quit in 2022
Incentivizing smoking cessation increases cessation through 12 weeks, but not at 26 weeks, when missing data are treated as smoking
Engagement with mobile chat-based intervention associated with higher abstinence rates at three and six months
Specifically, vaping products, varenicline, and heated tobacco products tied to significantly greater odds of successful cessation
Significantly more patients receiving cytisinicline versus placebo had continuous e-cigarette abstinence at the end of treatment
Benefit seen with additional six weeks of treatment after six weeks of initial failure with varenicline or nicotine replacement